ViiV Healthcare and Janssen Pharmaceutical Cos. have reported positive top-line data from the Phase IIII ATLAS study with another of its two-drug regimens for the treatment of HIV/AIDS, this time with a once-monthly injectable combination, giving a boost to their overall development strategy of reducing the pill burden for patients, while maintaining efficacy.
With a plethora of agents available to treat HIV/AIDS, developers like ViiV Healthcare and Janssen have turned some of their...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)